Regulatory gene mutations affecting apolipoprotein gene expression: Functions and regulatory behavior of known genes may guide future pharmacogenomic approaches to therapy

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 411-424

  Zannis, Vassilis I ^a,b   Liu, Tong ^a   Zanni, Markella ^a   Kan, Horng Yuan ^a   Kardassis, Dimitris ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

ApoA I, apoCIII, apoCIII enhancer; ApoE apoCI apoCIV apoCII; Gene regulation; HNF 4; Hormone nuclear receptors; Sp1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; DNA; HEPATOCYTE NUCLEAR FACTOR 4; LIPID;

BINDING SITE; CONTROLLED STUDY; DNA POLYMORPHISM; DYSLIPIDEMIA; ENHANCER REGION; FUTUROLOGY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SPECIES DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, REGULATOR; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; PHARMACOGENETICS; PHOSPHOPROTEINS; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSCRIPTION FACTORS;

MAMMALIA; MUS MUSCULUS;

EID: 0037721471     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.064     Document Type: Review

References (51)

1. Gumucio DL, Rood KL, Gray TA, Riordan MF, Sartor CI, Collins FS. Nuclear proteins that bind the human gamma-globin gene promoter: alterations in binding produced by point mutations associated with hereditary persistence of fetal hemoglobin. Mol Cell Biol 1988; 8:5310-22.
2. Ottolenghi S, Nicolis S, Taramelli R, Malgaretti N, Mantovani R, Comi P, et al. Sardinian G gamma-HPFH: a T-C substitution in a conserved "octamer" sequence in the G gamma-globin promoter. Blood 1988; 71:815-7.
3. Ottolenghi S, Camaschella C, Comi P, Giglioni B, Longinotti M, Oggiano L, et al. A frequent A gamma-hereditary persistence of fetal hemoglobin in northern Sardinia: its molecular basis and hematologic phenotype in heterozygotes and compound heterozygotes with beta-thalassemia. Hum Genet 1988; 79:13-7.
4. Gumucio DL, Rood KL, Blanchard-McQuate KL, Gray TA, Saulino A, Collins FS. Interaction of Sp1 with the human gamma globin promoter: binding and transactivation of normal and mutant promoters. Blood 1991; 78:1853-63.
5. Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briet E. The putative factor IX gene promoter in hemophilia B Leyden. Blood 1988; 72:1074-6.
6. Picketts DJ, Mueller CR, Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994; 84:2992-3000.
7. Reijnen MJ, Peerlinck K, Maasdam D, Bertina RM, Reitsma PH. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82:151-8.
8. Picketts DJ, Lillicrap DP, Mueller CR. Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation. Nat Genet 1993; 3:175-9.
9. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377-9.
10. Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 345:444-6.
11. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease. New York: McGraw-Hill, 1977:672-712.
12. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 1982; 23:1224-35.
13. Mehrabian M, Wong J, Wang X, Jiang Z, Shi W, Fogelman AM, Lusis AJ. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001; 89:125-30.
14. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91:120-6.
15. Zhang Q, Liu B, Liu Y, Fan P, Zhang R, Wu Z, et al. [DNA polymorphisms of apolipoprotein A I gene in Chinese endogenous hypertriglyceridemics]. Hua Xi Yi Ke Da Xue Xue Bao 1997; 28:233-8.
16. Patsch W, Sharrett AR, Chen IY, Lin-Lee YC, Brown SA, Gotto AM Jr., Boerwinkle E. Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans. Arterioscler Thromb 1994; 14:874-83.
17. Marcil M, Boucher B, Krimbou L, Solymoss BC, Davignon J, Frohlich J, Genest J Jr. Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization. Arterioscler Thromb Vasc Biol 1995; 15:1015-24.
18. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest 1992; 89: 1796-800.
19. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001; 158:173-81.
20. Marcais C, Bernard S, Merlin M, Ulhmann M, Mestre B, Rochet-Mingret L, et al. Severe hypertriglyceridaemia in type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency. Diabetologia 2000; 43:1346-52.
21. Meng X, Zhang G, Li P, Du Y. [DNA polymorphisms and haplotypes in the apoAI-CIII gene region and coronary heart disease]. Yi Chuan Xue Bao 1990; 17:411-7.
22. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90:4562-6.
23. Talianidis I, Tambakaki A, Toursounova J, Zannis VI. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry 1995; 34:10298-309.
24. Kardassis D, Tzameli I, Hadzopoulou-Cladaras M, Talianidis I, Zannis V. Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements. Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites. Arterioscler Thromb Vasc Biol 1997; 17:222-32.
25. Ogami K, Hadzopoulou-Cladaras M, Cladaras C, Zannis VI. Promoter elements and factors required for hepatic and intestinal transcription of the human ApoCIII gene. J Biol Chem 1990; 265:9808-15.
26. Ktistaki E, Lacorte JM, Katrakili N, Zannis VI, Talianidis I. Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene. Nucleic Acids Res 1994; 22:4689-96.
27. Kan HY, Georgopoulos S, Zannis V. A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice. J Biol Chem 2000; 275:30423-31.
28. Georgopoulos S, Kan HY, Reardon-Alulis C, Zannis V. The SP1 sites of the human apoCIII enhancer are essential for the expression of the apoCIII gene and contribute to the hepatic and intestinal expression of the apoA-I gene in transgenic mice. Nucleic Acids Res 2000; 28:4919-29.
29. Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol 2001; 12:181-207.
30. Lavrentiadou SN, Hadzopoulou-Cladaras M, Kardassis D, Zannis VI. Binding specificity and modulation of the human ApoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors. Biochemistry 1999; 38:964-75.
31. Papazafiri P, Ogami K, Ramji DP, Nicosia A, Monaci P, Cladaras C, Zannis VI. Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites. J Biol Chem 1991; 266:5790-7.
32. Tzameli I, Zannis VI. Binding specificity and modulation of the ApoA-I promoter activity by homo- and heterodimers of nuclear receptors. J Biol Chem 1996; 271:8402-15.
33. Kardassis D, Falvey E, Tsantili P, Hadzopoulou-Cladaras M, Zannis V. Direct physical interactions between HNF-4 and Sp1 mediate synergistic transactivation of the apolipoprotein CIII promoter. Biochemistry 2002; 41:1217-28.
34. Simonet WS, Bucay N, Lauer SJ, Taylor JM. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem 1993; 268:8221-9.
35. Dang Q, Walker D, Taylor S, Allan C, Chin P, Fan J, Taylor J. Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus. J Biol Chem 1995; 270: 22577-85.
36. Allan CM, Walker D, Taylor JM. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. J Biol Chem 1995; 270:26278-81.
37. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 1997; 272:29113-9.
38. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem 2000; 275:31567-72.
39. Giguere V. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 1994; 15:61-79.
40. Mangelsdorf DJ, Umesono K, Evans RM. The retinoids: biology, chemistry and medicine. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids: biology, chemistry and medicine. New York: Raven Press Ltd., 1994:319-49.
41. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev 1994; 15:391-407.
42. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55:767-72.
43. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hyper-triglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249:790-3.
44. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-53.
45. Kypreos KE, van Dijk KW, van Der ZA, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem 2001; 276: 19778-86.
46. Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. Genes Dev 2000; 14:464-74.
47. Chang DJ, Paik YK, Leren TP, Walker DW, Howlett GJ, Taylor JM. Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors. J Biol Chem 1990; 265:9496-504.
48. Simonet WS, Bucay N, Pitas RE, Lauer SJ, Taylor JM. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem 1991; 266:8651-4.
49. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics 1995; 28:291-300.
50. Dang Q, Taylor J. In vivo footprinting analysis of the hepatic control region of the human apolipoprotein E/C-I/C-IV/C-II gene locus. J Biol Chem 1996; 271:28667-76.
51. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci 2001; 21:812-22.